We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




European Neurologic-Monitoring Market

By HospiMedica staff writers
Posted on 25 Oct 2006
The increasing prevalence of neurologic problems, concomitant with technology advances, are supporting high-growth potential in the European neurologic-monitoring market.

The rising incidence of epilepsy in developed nations and heightened awareness about sleep disorders, coupled with the rapid rise of sleep labs and sleep clinics, has greatly motivated and influenced the growth of the neurologic-monitoring market in such disorders. More...
However, the presence of well established participants and market saturation, together with a stagnant competitive landscape, is posing a serious challenge for newer companies to enter the market.

"Neurological monitoring is a technologically advanced market and is poised to revolutionize the monitoring of neurological parameters,” said C.R. Hema Varishika, a research analyst with Frost & Sullivan (Palo Alto, CA, USA), an international consulting company. "Market participants have shifted their focus towards new applications, like long-term monitoring of conditions such as epilepsy and sleep disorders that will drive market growth.”

"In this market with rising health expenditures and an unstable economy, tactical and well calculated measures have to be taken to develop and promote one's products,” cautioned Ms. Varshika. "Product development initiatives need to be based on research in emerging areas and be supported by strategic marketing. Proactive alliances and tactical marketing plans followed by effective execution will enable expansion in market share.”

According to Frost & Sullivan, the European neurologic-monitoring market earned revenues of $135.2 million in 2005 and is anticipated to reach $175.3 million in 2012.



Related Links:
Frost & Sullivan

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Syringes
Prefilled Saline Flush Syringes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.